44.98
3.38%
1.47
Kymera Therapeutics Inc (KYMR) 最新ニュース
(KYMR) Trading Report - Stock Traders Daily
Jennison Associates LLC Purchases 368,394 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens - MarketBeat
US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Stephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight Recommendation - MSN
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7%Here's What Happened - MarketBeat
Avoro Capital Advisors LLC Expands Stake in Kymera Therapeutics Inc - GuruFocus.com
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
FMR LLC Bolsters Stake in Kymera Therapeutics Inc - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $51.21 Average Price Target from Analysts - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00 at Morgan Stanley - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Kymer - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Kymera Therapeutics to Present at 5 Major Healthcare Investor Conferences in November | KYMR Stock News - StockTitan
Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Immunology to take front seat at Kymera - The Pharma Letter
Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia
Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance
FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World
Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
(KYMR) Long Term Investment Analysis - Stock Traders Daily
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN
Guggenheim Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00 - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat
The Latest Analyst Ratings For Kymera Therapeutics - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia
Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownWhat's Next? - MarketBeat
Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com
Preview: Kymera Therapeutics's Earnings - Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
大文字化:
|
ボリューム (24 時間):